Market Overview

UPDATE: Piper Jaffray Downgrades Affymax to Neutral Following Omontys Recall


Piper Jaffray downgraded Affymax (NASDAQ: AFFY) from Overweight to Neutral and removed the $37.00 price target.

Piper Jaffray commented, "We are downgrading AFFY to Neutral following a voluntary safety recall of Omontys. We expect the stock to approach cash value (~$2 per share) tomorrow as investors take into account the lack of visibility on reintroduction of the drug and more importantly the difficult task of repairing a negative safety perception. This combined with a potential delay in approval in Europe and need for additional financing in the future could prevent the stock from recovering in the next 6-9 months."

Affymax closed at $16.52 on Friday.

Latest Ratings for AFFY

Mar 2013DowngradesSell
Feb 2013DowngradesBuyNeutral
Feb 2013DowngradesMarket OutperformMarket Underperform

View More Analyst Ratings for AFFY
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Downgrades Analyst Ratings


Related Articles (AFFY)

View Comments and Join the Discussion!

Latest Ratings

TOLGoldman SachsInitiates Coverage On42.0
KBHGoldman SachsInitiates Coverage On36.0
YEXTSunTrust Robinson HumphreyMaintains28.0
LHCGSunTrust Robinson HumphreyMaintains160.0
DLRSunTrust Robinson HumphreyMaintains140.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Qihoo 360 Wins Ministry of Commerce Contract for Enterprise Internet Security Solutions

UPDATE: JP Morgan Maintains Neutral on SeaCube Despite Lower-Than-Expected Earnings, Raises PT to $23